Relapsing-Remitting MS

Who is eligible to participate in the EVOLVE-MS-1 study?

To be eligible for this study, you must:

  • Be 18 to 65 years of age
  • Have been diagnosed with RRMS
  • Not have a diagnosis of primary progressive, secondary progressive, or progressive relapsing MS

Other eligibility criteria apply. All study-related visits, tests, and the study drug (ALKS 8700) will be provided at no cost to you. In addition, reimbursement for study-related expenses may be provided.

What are the risks and benefits related to the EVOLVE-MS-1 study?

While ALKS 8700 could be helpful in treating your RRMS, there is no guarantee that participating in this study will help your condition, and it is possible your RRMS could still progress. You may also experience side effects.

In previous studies of ALKS 8700, the most common side effect was flushing (redness, sensation of warmth, and/or itching of the skin). The study staff will provide you with a complete list of possible side effects related to the experimental drug and this study.

Because research studies can affect the health and safety of participants, you will be closely monitored during this study. Researchers for this study designed a protocol, which explains all of the study procedures in complete detail. An independent review board responsible for participant safety reviewed and approved this protocol and requires that it be followed exactly.

What if I have questions?

The EVOLVE-MS-1 study staff is always available to answer any questions or concerns you may have about the study or the experimental drug.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *